Literature DB >> 12062560

Trypanosoma cruzi reinfections in mice determine the severity of cardiac damage.

Juan M Bustamante1, Héctor W Rivarola, Alicia R Fernández, Julio E Enders, Ricardo Fretes, José A Palma, Patricia A Paglini-Oliva.   

Abstract

In two murine models we studied Trypanosoma cruzi reinfection in the acute and chronic phase of experimental Chagas' disease in order to elucidate the relevance of reinfections in determining the variability of cardiac symptoms and the irreversible cardiac damage. They were followed for 120 and 600 days post infection (p.i.) for the acute and chronic model, respectively. Reinfected mice reached higher parasitaemia levels than infected mice. The survival was 33 and 21% in the chronic phase for mice reinfected in the acute phase and 13% for mice reinfected in the chronic stage at the end of the experiments. Sixty-six percent of the infected group presented electrocardiographic abnormalities (heart frequency, prolonged PQ segment or QRS complex) in the chronic stage whereas 100% of the reinfected animals exhibited electric cardiac dysfunction since 90 and 390 days p.i. for the acute and chronic reinfected model, respectively (P<0.01). Heart histopathological studies showed fibrosis and necrosis areas and mononuclear infiltrates supporting the view that parasite persistence is a major factor in continuing the tissue inflammation. This work shows that T. cruzi reinfections could be related to the variability and severity of the clinical course of Chagas' disease and that parasite persistence is involved in exacerbation of the disease.

Entities:  

Mesh:

Year:  2002        PMID: 12062560     DOI: 10.1016/s0020-7519(02)00023-1

Source DB:  PubMed          Journal:  Int J Parasitol        ISSN: 0020-7519            Impact factor:   3.981


  23 in total

1.  Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations.

Authors:  Simone Garcia; Carolina O Ramos; Juliana F V Senra; Fabio Vilas-Boas; Maurício M Rodrigues; Antonio C Campos-de-Carvalho; Ricardo Ribeiro-Dos-Santos; Milena B P Soares
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

2.  Reinfections and Trypanosoma cruzi strains can determine the prognosis of the chronic chagasic cardiopathy in mice.

Authors:  Juan M Bustamante; Mónica Novarese; Héctor W Rivarola; María S Lo Presti; Alicia R Fernández; Julio E Enders; Ricardo Fretes; Patricia A Paglini-Oliva
Journal:  Parasitol Res       Date:  2007-02-15       Impact factor: 2.289

3.  ECG detection of murine chagasic cardiomyopathy.

Authors:  Christopher S Eickhoff; Cade T Lawrence; John E Sagartz; Leesa A Bryant; Arthur J Labovitz; Simil S Gala; Daniel F Hoft
Journal:  J Parasitol       Date:  2010-08       Impact factor: 1.276

Review 4.  Role of complement C5a and histones in septic cardiomyopathy.

Authors:  Fatemeh Fattahi; Lynn M Frydrych; Guowu Bian; Miriam Kalbitz; Todd J Herron; Elizabeth A Malan; Matthew J Delano; Peter A Ward
Journal:  Mol Immunol       Date:  2018-06-18       Impact factor: 4.407

5.  Autonomic dysfunction and risk factors associated with Trypanosoma cruzi infection among children in Arequipa, Peru.

Authors:  Natalie M Bowman; Vivian Kawai; Robert H Gilman; Cesar Bocangel; Gerson Galdos-Cardenas; Lilia Cabrera; Michael Z Levy; Juan Geny Cornejo del Carpio; Freddy Delgado; Lauren Rosenthal; Vivian V Pinedo-Cancino; Francis Steurer; Amy E Seitz; James H Maguire; Caryn Bern
Journal:  Am J Trop Med Hyg       Date:  2011-01       Impact factor: 2.345

6.  Influence of pregnancy on Trypanosoma cruzi parasitemia in chronically infected women in a rural Bolivian community.

Authors:  Laurent Brutus; Jean-Christophe Ernould; Jorge Postigo; Mario Romero; Dominique Schneider; José-Antonio Santalla
Journal:  Am J Trop Med Hyg       Date:  2011-05       Impact factor: 2.345

7.  Risk progression to chronic Chagas cardiomyopathy: influence of male sex and of parasitaemia detected by polymerase chain reaction.

Authors:  A L Basquiera; A Sembaj; A M Aguerri; M Omelianiuk; S Guzmán; J Moreno Barral; T F Caeiro; R J Madoery; O A Salomone
Journal:  Heart       Date:  2003-10       Impact factor: 5.994

Review 8.  Complement and sepsis-induced heart dysfunction.

Authors:  Fatemeh Fattahi; Peter A Ward
Journal:  Mol Immunol       Date:  2016-12-05       Impact factor: 4.407

9.  Fexinidazole: a potential new drug candidate for Chagas disease.

Authors:  Maria Terezinha Bahia; Isabel Mayer de Andrade; Tassiane Assíria Fontes Martins; Álvaro Fernando da Silva do Nascimento; Lívia de Figueiredo Diniz; Ivo Santana Caldas; André Talvani; Bernadette Bourdin Trunz; Els Torreele; Isabela Ribeiro
Journal:  PLoS Negl Trop Dis       Date:  2012-11-01

10.  Prevalence of Chagas heart disease in a region endemic for Trypanosoma cruzi: evidence from a central Bolivian community.

Authors:  Jessica E Yager; Daniel F Lozano Beltran; Faustino Torrico; Robert H Gilman; Caryn Bern
Journal:  Glob Heart       Date:  2015-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.